Bimoclomol (BRLP-42) ameliorates peripheral neuropathy in streptozotocin-induced diabetic rats

Brain Research Bulletin

Volumn 44, Issue 3, 1997, Pages 259-263

  Bíró, Katalin ^a   Jednákovits, Andrea ^a   Kukorelli, Tibor ^b   Hegedus, Erzsébet ^b   Korányi, László ^a  

^a Biorex Research and Development Co   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Linolenic acid; Ischaemic resistance; Nerve conduction; Neuroprotection; Sciatic nerve

Indexed keywords

BIMOCLOMOL; BRLP 42; LINOLEIC ACID; STREPTOZOCIN; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG EFFECT; ISCHEMIA; MALE; MOTOR NERVE CONDUCTION; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY NERVE CONDUCTION; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ELECTROMYOGRAPHY; GAMMA-LINOLENIC ACID; ISCHEMIA; MALE; NEURAL CONDUCTION; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; SCIATIC NERVE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0030760940     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(97)00118-4     Document Type: Article

References (38)

1. Baynes, J. W. Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-412; 1991.
2. Bíró, K.; Jednákovits, A.; Jaszlits, L.; Hegedüs, E.; Kukorelli, T.; Bácsy, E. Effect of BRLP-42 on streptozotocin induced early signs of neuropathy and retinopathy. 15th International Diabetes Federation Congress, Nov. 6-11: Kobe, Japan, Abstracts 08A5PP0584; 1994:300.
3. Cameron, N. E.; Cotter, M. A.; Low, P. A. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am. J. Physiol. 261:E1-E8; 1991.
4. Cameron, N. E.; Cotter, M. A.; Robertson, S. Essential fatty acid diet supplementation: Effects on peripheral nerve and skeletal muscle function and capillarization in streptozocin-induced diabetic rats. Diabetes 40:532-539; 1991.
5. +-ATPase activity, and vascular supply in STZ-D rats. Diabetes 40:1652-1658; 1991.
6. Cameron, N. E.; Cotter, M. A.; Robertson, S. Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin diabetic rats. Diabetologia 35:12-18; 1992.
7. Cameron, N. E.; Cotter, M. A. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: Evidence from Experimental studies. Diabetic Med. 10:593-605; 1993.
8. Cameron, N. E.; Cotter, M. A.; Dines, K. C.; Maxfield, E. K. Pharmacological manipulation of vascular endothelium in non-diabetic and streptozotocin-diabetic rats: Effects on nerve conduction, hypoxic resistance and endoneurial capillarization. Diabetologia 36:516-522; 1993.
9. Cameron, N. E.; Cotter, M. A. Mechanisms underlying impaired nerve perfusion and endoneurial oxygenation in experimental diabetes: Potential treatment strategies. In: Hotta, N.; Greene, D. A.; Ward, J. D.; Sima, A. A. F.; Boulton, A. J. M., eds. Diabetic neuropathy: New concepts and insights. Amsterdam: Elsevier; 1995:3-15.
10. Cameron, N. E.; Cotter, M. A.; Basso, M.; Hohman, T. C. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40:271-281; 1997.
11. De Koning, P.; Gispen, W. H. Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 8:415-422; 1987.
12. Dines, C.; Cotter, M. A.; Cameron, N. E. Contrasting effects of treatment with ω-3 and ω-6 essential fatty acids on peripheral nerve function and capillarization in streptozotocin-diabetic rats. Diabetologia 36:1132-1138; 1993.
13. Eaton, R. P.; Quails, C.; Bicknell, J.; Sibbitt, J.; King, M. K.; Griffey, R. H. Structure-function relationships within peripheral nerves in diabetic neuropathy: The hydration hypothesis. Diabetologia 39:439-446; 1996.
14. Ganea, E.; Harding, J. J. Molecular chaperones protect against glycation-induced inactivation of glucose-6-phosphate dehydrogenase. Eur. J. Biochem. 231:181-185; 1996.
15. Greene, D. A.; Stevens, M. J. Interaction of metabolic and vascular factors in the pathogenesis of diabetic neuropathy. In: Hotta, N.; Greene, D. A.; Ward, J. D.; Sima, A. A. F.; Boulton, A. J. M., eds. Diabetic neuropathy: New concepts and insights. Amsterdam: Elsevier; 1995:37-41.
16. Heath, M. M.; Rixon, K. C.; Harding, J. J. Glycation-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperons, alpha-crystallin. Biochem. Biophys. Acta 1315:176-184; 1996.
17. Horrobin, D. F. γ-Linolenic acid. Rev. Contemp. Pharmacother. 1:1-45; 1990.
18. Jaszlits, L.; Jednákovits, A.; Koltai, M. Zs.; Bíró, K.; Hegedüs, E.; Udvardy, E.; Vereczkey, L.; Literáti-Nagy, P. Antiischemic efficacy of BRLP-42. J. Mol. Cell Cardiol. 25 (Suppl. I): XI P 20; 1993.
19. Kihara, M.; Low, P. A. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp. Neurol. 132:180-185; 1995.
20. Low, P. A.; Ward, K.; Schmelzer, J. D.; Brimijoin, S. Ischaemic conduction failure and energy metabolism in experimental diabetic neuropathy. Am. J. Physiol. 248:E457-E462; 1985.
21. Low, P. A.; Lagerhund, T. D.; McManis, P. G. Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int. Rev. Neurobiol. 31:355-438; 1989.
22. Malik, R. A.; Tesfaye, S.; Veves, A.; Sharma, A. K.; Ward, J. D.; Boulton, A. J. M. The progression of microangiopathy with neuropathic severity. In: Hotta, N.; Greene, D. A.; Ward, J. D.; Sima, A. A. F.; Boulton, A. J. M., eds. Diabetic neuropathy: New concepts and insights. Amsterdam: Elsevier; 1995:131-135.
23. Marfaing-Jallat, P.; Portha, B.; Pénicaud, L. Altered conditioned taste aversion and glucose utilization in related brain nuclei of diabetic GK rats. Brain Res. Bull. 37:639-643; 1995.
24. Pharmaproject BRLP-42 symptomatic antidiabetic (A10C): (UN) Phase I Clinical Trial 1995.
25. Plumier, J. C.; Ross, B. M.; Currie, R. W.; Angelidis, C. E.; Kazlaris, H.; Pagoulatos, G. N. Transgenic mice expressing the human heat shock protein 70 have improved post-ichemic myocardial recovery. J. Clin. Invest. 95:1845-1860; 1995.
26. Rebeiro, S. P.; Villar, J.; Slutsky, A. S. Induction of the stress response to prevent organ injury. New Horiz. 3:301-311; 1995.
27. Sango, K.; Horie, H.; Okamura, A.; Inoue, S.; Takenaka, T. Diabetes impairs DRG neuronal attachment to extracellular matrix protein in vitro. Brain Res. Bull. 37:533-537; 1995.
28. Schmelzer, J. D.; Zochodne, D. W.; Low, P. A. Ischemic and reperfusion injury of rat peripheral nerve. Proc. Natl. Acad. Sci. USA 86:1639-1642; 1989.
29. Sima, A. A. F.; Nathaniel, V.; Prashar, A.; Bril, V.; Greene, D. A. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor. Diabetes 40:1090-1099; 1991.
30. Sima, A. A. F.; Prashar, A.; Nathaniel, V.; Bril, V.; Werb, M. R.; Greene, D. A. Overt diabetic neuropathy: Repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabetes Med. 10:115-121; 1993.
31. Stanley, E. F. Sensory and motor nerve conduction velocities and the latency of the H-reflex during growth of the rat. Exp. Neurol. 71:497-506; 1981.
32. Tesfaye, S.; Malik, R.; Ward, J. D. Vascular factors in diabetic neuropathy: Review. Diabetologia 37:847-854; 1994.
33. Tomlinson, D. R.; Willars, G. B.; Carrington, A. L. Aldose reductase inhibitors and diabetic complications. Pharmacol. Ther. 54:151-194; 1992.
34. Tuck, R. R.; Schmelzer, J. D.; Low, P. A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107:935-950; 1984.
35. Vigh, L.; Literáti, N. P.; Horváth, I.; Török, Zs.; Balogh, G.; Glatz, A.; Kovács, E.; Duda, E.; Boros, I.; Ferdinándy, P.; Multhoff, G.; Farkas, B.; Jaszlits, L.; Korányi, L.; Maresca, B. BRLP-42, a new generation of drugs acting as a chaperone inducer. In: Molecular chaperones and the heat shock response. New York: GSH; 1996:345.
36. Vlassara, H.; Bucala, R. Recent progress in advanced glycation and diabetic vascular disease: Role of advanced glycation end product receptors. Diabetes 45(Suppl. 3):S65-S69; 1996.
37. Yagihashi, S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes/Metab. Rev. 11:193-225; 1995.
38. Ziegler, D.; Mühlen, H.; Rathmann, W.; Gries, F. A. Effects on one year treatment with γ-linolenic Acid (EFS) on diabetic neuropathy. Diabetes 42(Suppl. 1):99A; 1993.